These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9787320)

  • 21. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
    Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapy of myelofibrosis: targeting pathogenesis.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.
    Wang JC; Chen C; Novetsky AD; Lichter SM; Ahmed F; Friedberg NM
    Am J Med; 1998 May; 104(5):451-5. PubMed ID: 9626028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
    Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
    Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Agnogenic myeloid metaplasia in pregnancy. Case report].
    Manole I; Costăchescu G; Aldea MJ; Gavriluţ M; Dumitraşcu I
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):465-9. PubMed ID: 20700988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia.
    Marvin KS; Spellberg RD
    Chest; 1993 Feb; 103(2):642-4. PubMed ID: 8432180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agnogenic myelofibrosis in children--a case report and review of the literature.
    Hamazaki M; Mugishima H
    Acta Pathol Jpn; 1981 Jan; 31(1):143-52. PubMed ID: 7234418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigation and management of patients presenting with thrombocytosis].
    Cheminant M; Delarue R
    Rev Med Interne; 2013 Aug; 34(8):465-71. PubMed ID: 23498669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7)].
    Hayashi S; Iwama H; Uchida Y; Kawakubo K; Inatomi Y; Nagasu M; Miyazawa K; Ohyashiki JH; Ohyashiki K; Toyama K
    Rinsho Ketsueki; 1997 May; 38(5):445-7. PubMed ID: 9194391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of splenectomy on hemostasis in agnogenic myeloid metaplasia.
    Brenner B; Tavori S; Tatarsky I
    Haemostasis; 1987; 17(3):141-6. PubMed ID: 3609915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ascites in agnogenic myeloid metaplasia: association with peritoneal implant of myeloid tissue and therapy.
    Patel NM; Kurtides ES
    Cancer; 1982 Sep; 50(6):1189-90. PubMed ID: 7104962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone marrow fibrosis in malignant hemopathies and cancers. Histological study of 2 786 biopsies (author's transl)].
    Duhamel G; Stachowiak J
    Sem Hop; 1981 Jan 18-25; 57(3-4):111-6. PubMed ID: 6261348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcoidosis and agnogenic myeloid metaplasia.
    Reich JM
    J Intern Med; 1994 Feb; 235(2):175-8. PubMed ID: 8308481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosome aberrations including der(6)t(2;6)(p15;p21.3) and der(22)t(3;22)(p21;p11) in the evolution of essential thrombocythemia to myelofibrosis with myeloid metaplasia.
    Lazarevic V; Andersson C; Wahlin A; Golovleva I
    Cancer Genet Cytogenet; 2006 Feb; 165(1):87-9. PubMed ID: 16490605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.